- Home
- SPRU vs AKTX Comparison
SPRU vs AKTX Comparison
Compare SPRU & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRU
- AKTX
- Stock Information
- Founded
- SPRU 2008
- AKTX N/A
- Country
- SPRU United States
- AKTX United States
- Employees
- SPRU N/A
- AKTX N/A
- Industry
- SPRU Auto Parts:O.E.M.
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPRU Consumer Discretionary
- AKTX Health Care
- Exchange
- SPRU Nasdaq
- AKTX Nasdaq
- Market Cap
- SPRU 34.9M
- AKTX 35.7M
- IPO Year
- SPRU N/A
- AKTX N/A
- Fundamental
- Price
- SPRU $1.55
- AKTX $0.99
- Analyst Decision
- SPRU
- AKTX Strong Buy
- Analyst Count
- SPRU 0
- AKTX 1
- Target Price
- SPRU N/A
- AKTX $5.00
- AVG Volume (30 Days)
- SPRU 3.8M
- AKTX 33.3K
- Earning Date
- SPRU 08-11-2025
- AKTX 08-22-2025
- Dividend Yield
- SPRU N/A
- AKTX N/A
- EPS Growth
- SPRU N/A
- AKTX N/A
- EPS
- SPRU N/A
- AKTX N/A
- Revenue
- SPRU $87,638,000.00
- AKTX N/A
- Revenue This Year
- SPRU $2.12
- AKTX N/A
- Revenue Next Year
- SPRU N/A
- AKTX N/A
- P/E Ratio
- SPRU N/A
- AKTX N/A
- Revenue Growth
- SPRU 9.48
- AKTX N/A
- 52 Week Low
- SPRU $1.13
- AKTX $0.85
- 52 Week High
- SPRU $3.35
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- SPRU 56.10
- AKTX 35.33
- Support Level
- SPRU $1.13
- AKTX $0.96
- Resistance Level
- SPRU $1.32
- AKTX $1.06
- Average True Range (ATR)
- SPRU 0.13
- AKTX 0.05
- MACD
- SPRU 0.03
- AKTX -0.01
- Stochastic Oscillator
- SPRU 67.74
- AKTX 14.89
About SPRU Spruce Power Holding Corporation
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.